GSK plc (GLAXF) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - General industry. The company is headquartered in Brentford, United Kingdom. The current CEO is Luke Victor Miels.
GLAXF has IPO date of 2010-01-05, 68,629 full-time employees, listed on the Other OTC, a market capitalization of $116.84B.
GSK plc is a global pharmaceutical and healthcare company headquartered in the United Kingdom, engaged in the discovery, development, and commercialization of prescription medicines, vaccines, and consumer health products across multiple therapeutic areas and markets worldwide. The company operates four primary business segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare, offering treatments in respiratory, HIV, oncology, immunology, cardiovascular, and other disease categories, alongside consumer wellness and oral health products. GSK maintains an extensive portfolio of consumer healthcare offerings including nasal sprays, tablets, lozenges, toothpastes, and topical formulations across multiple dosage forms. The company strengthens its innovation pipeline through strategic collaborations with leading biotechnology firms including Novartis, Sanofi, and Vir Biotechnology, positioning itself as a diversified player in both prescription pharmaceuticals and consumer health markets. Founded in 1715 and rebranded as GSK plc in 2022, the company maintains significant operations across the United Kingdom, United States, and international markets.
